{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T19:40:24Z","timestamp":1756150824696,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,5,21]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>The use of enoxaparin is generally not recommended in patients with end-stage renal disease (ESRD) and undergoing haemodialysis. We describe the administration of high-dose enoxaparin in a haemodialysis patient with heparin resistance and recurrent deep vein thrombosis (DVT) outlining a novel dosing regimen along an innovative method for monitoring antifactor Xa activity. As a last resort of his recurrent DVT, a critically ill intensive care unit patient undergoing dialysis was prescribed high-dose enoxaparin, administered exclusively after dialysis, on dialysis days for a period of 2\u2009months. Antifactor Xa activity was measured 4\u2009hours postadministration with a target range of 0.7\u20131.2\u2009IU\/mL. The patient\u2019s DVT demonstrated clinical improvement, antifactor Xa levels were maintained within the therapeutic range and haemoglobin levels remained stable with no signs of bleeding. This case reports the implementation of a high-dose enoxaparin dosing and monitoring strategy in a high-risk patient. However, further studies involving larger patient cohorts are required to validate this approach.<\/jats:p>","DOI":"10.1136\/bcr-2024-262939","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T19:05:19Z","timestamp":1756148719000},"page":"e262939","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Using and monitoring of therapeutic high-dose enoxaparin in a heparin-resistant dialysis patient with recurrent thromboembolic events"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-1477","authenticated-orcid":false,"given":"Dania","family":"Ghaziri","sequence":"first","affiliation":[{"name":"Department of Pharmacy, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayan","family":"Mohamad","sequence":"additional","affiliation":[{"name":"Pulmonary and critical care division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-6111","authenticated-orcid":false,"given":"Ayman","family":"Bsat","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Bou Akl","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2025082512051125000_18.8.e262939.1","unstructured":"Jupalli A , Iqbal AM . Enoxaparin. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539865\/"},{"key":"2025082512051125000_18.8.e262939.2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006289975"},{"key":"2025082512051125000_18.8.e262939.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.036"},{"key":"2025082512051125000_18.8.e262939.4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ki.2013.163","article-title":"Use of enoxaparin in end-stage renal disease","volume":"84","author":"Lai","year":"2013","journal-title":"Kidney Int"},{"key":"2025082512051125000_18.8.e262939.5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3949\/ccjm.91a.23017","article-title":"Management of venous thromboembolism in patients with active cancer","volume":"91","author":"Dave","year":"2024","journal-title":"CCJM"},{"key":"2025082512051125000_18.8.e262939.6","doi-asserted-by":"crossref","unstructured":"Sam Schulman Thrombosis and Atherosclerosis Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; and Karolinska Institute, Stockholm, Sweden. 2017. Available: https:\/\/doi.org\/10.1182\/blood-2017-03-742304","DOI":"10.1182\/blood-2017-03-742304"},{"key":"2025082512051125000_18.8.e262939.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291"},{"key":"2025082512051125000_18.8.e262939.8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-139X.2001.00066.x"},{"key":"2025082512051125000_18.8.e262939.9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/8755122520988728","article-title":"Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature","volume":"37","author":"Amani","year":"2021","journal-title":"J Pharm Technol"},{"key":"2025082512051125000_18.8.e262939.10","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1055\/s-0040-1713683","article-title":"Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice","volume":"4","author":"Hendriks","year":"2020","journal-title":"TH Open"},{"key":"2025082512051125000_18.8.e262939.11","doi-asserted-by":"publisher","DOI":"10.1177\/8755122516646384"},{"key":"2025082512051125000_18.8.e262939.12","first-page":"273","article-title":"Gastrointestinal dysmotility in critically ill patients","volume":"31","author":"Ladopoulos","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"2025082512051125000_18.8.e262939.13","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611060-00005"},{"key":"2025082512051125000_18.8.e262939.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.06.017"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-262939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T19:05:21Z","timestamp":1756148721000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-262939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,25]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bcr-2024-262939"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-262939","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}